Ka Lung W.
- Country
- Belgium
- Department
- ZAS Middelheim
Research Overview
- TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma
- A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
- Phase 2 Study on Epcoritamab Monotherapy or Combined with Lenalidomide for Anthracycline-Ineligible Diffuse Large B-Cell Lymphoma Patients
Data & Insights
Has run more than one trial at 312 of 466 partner sites.
Specializations
Multiple Myeloma Research
Specializes in investigating innovative treatments for multiple myeloma, including both newly diagnosed and relapsed/refractory cases. Focuses on evaluating novel therapeutic combinations involving monoclonal antibodies and targeted therapies.
- Treatment-resistant myeloma
- Early-stage disease management
- Novel drug combinations
Lymphoma Studies
Conducts research in various lymphoma subtypes, with particular emphasis on Hodgkin lymphoma and diffuse large B-cell lymphoma. Investigates response-adapted therapy approaches and targeted treatment strategies.
- Advanced stage lymphomas
- B-cell lymphoma therapies
- PET-guided treatment
Emerging Therapeutics
Leads investigations into immunotherapy approaches and targeted molecular therapies. Studies novel agents including monoclonal antibodies, CAR T-cell therapy, and combination treatment strategies.
- Antibody-based therapies
- Cellular therapy
- Treatment sequencing
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.